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Abstract
Background: The objective of this study was to assess the efficacy of intra-articular injections of hyaluronic acid
(HA) and a novel, on-site conjugate of HA with autologous fibrinogen in platelet-rich plasma (HA-PRP) in a canine
model of osteoarthritis (OA)
Methods: Twelve beagle dogs underwent a unilateral resection of the cranial cruciate ligament (CrCL) of the stifle
joint. Clinical and radiographic signs of OA were confirmed in all dogs 8 weeks following CrCL resection and prior
to treatment. The dogs were randomized into three groups: saline (n = 4), HA (n = 4), and HA-PRP (n = 4). Each
dog received intra-articular injections of the respective substance into the affected joint at pre-determined time
points. The dogs were assessed for adverse effects for 3 days after each injection and for lameness, pain, range of
motion, kinetics, and radiographic OA severity prior to treatment and 3 months after injection. OA severity as
determined by radiographic examination was not significantly different among the groups at any time point. The
dogs were then humanely euthanatized and the stifle joint assessed by gross and histological examinations.
Results: Dogs treated with four weekly injections of HA or two biweekly injections of HA-PRP were significantly (p <
0.05) better than dogs treated with four weekly injections of saline at 2-, 4-, and 12-week time points based on a
comfortable range of motion (CROM) and clinical lameness score. Gait analysis measuring symmetry and weight
distribution on pressure sensor walkway showed significantly (p < 0.05) improved limb function for dogs treated with
HA and HA-PRP compared with dogs treated with saline yet with better clinical outcome for the HA-PRP-treated group
at 12 and 20weeks follow-up. Gross and histological analysis of synovium and articular cartilage demonstrated
significant (p < 0.05) improvement by both treatments groups compared to controls. There was however significantly
(p < 0.05) less damage to the cartilage in the HA-PRP group compared to the HA-treated group.
Conclusions: These data suggest that while injection of HA and HA-PRP may be sufficient for short-term amelioration
of the symptoms associated with OA, treatment with HA-PRP conjugates may be superior, providing significantly better
long-term cartilage preservation.
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Background
Osteoarthritis (OA) is a debilitating joint disease, often
secondary to structural abnormalities or ligament injury
leading to articular instability and transformations of the
normal cartilage matrix resulting in pain, stiffness of
joints, and muscle atrophy [1, 2]. OA is the most com-
mon type of arthritis related to age and currently defined
as an incurable disease. Moreover, the inflammatory
process can affect the progression of the disease [3, 4].
The most important goal of treatments for osteoarth-
ritis is to alleviate pain. Pain management allows the
patient to regain strength and function and maintain the
movability of the affected limb [5]. Other goals of treat-
ment include the maintenance of joint flexibility, im-
provement of the patient’s quality of life, and potentially
a delay in disease progression [6]. The most common
methods for managing OA-related symptoms are the
administration of non-steroidal anti-inflammatory drugs
(NSAIDs), nutritional supplementation, physiotherapy,
and weight management. The main adverse effects of
NSAIDs are associated with the gastrointestinal tract,
the kidney, and the impairment of platelet activity [7].
Alternatively, intra-articular injections of hyaluronic acid
(HA) are gaining popularity in a number of countries as
the first-line symptomatic treatment for diarthrodial
osteoarthritis [8]. This treatment approach is based on
the elastic properties of HA, increasing the lubricating
properties similar to that of the synovial fluid in OA
joints. Furthermore, HA can directly induce endogenous
HA synthesis and has endogenous anti-inflammatory
and antinociceptive properties [9, 10].
Platelet-rich plasma (PRP) is a concentrate of autologous
platelets introduced recently also as an intra-articular agent
to alleviate OA symptoms in animal and human medicine
[11–15]. It is based on the intra-articular delivery of a large
pool of growth factors and other bioactive proteins released
from autologous platelet-rich preparations. Various growth
factors (fibroblast growth factor [FGF], insulin-like growth
factor [IGF], platelet-derived growth factor [PDGF], trans-
forming growth factor-β [TGF-β], vascular endothelial
growth factor [VEGF], etc.) released by the activated plate-
lets serve critical roles in physiological processes such as
wound healing and tissue regeneration. PRP contains not
only platelets and growth factors but also fibrinogen, fibro-
nectin, and other macromolecules that assist the healing
process. Many of these growth factors and proteins have
been found to take part also in the preservation and regen-
eration of articular cartilage, which given its avascular
nature does not undergo spontaneous healing or regener-
ation. Last, platelets have also shown some analgesic and
lubricating properties [16].
Although the interest in intra-articular viscosupple-
mentation for the treatment of joint diseases is on the
rise, it remains challenging mainly due to the rapid
elimination of HA from the joint space through the syn-
ovial capillaries (for low-molecular HA) or the lymphatic
vessels (for high-molecular HA) [17–19]. In addition,
due to HA’s limited clinical efficacy, intra-articular drug
delivery systems (DDS) are also gaining interest in joint
regenerative medicine, with the objective of improving
clinical and structural outcome [17, 19]. Hydrogels in
particular have received significant attention as intra-ar-
ticular drug delivery vehicle due to their biological and
rheological properties, and high-molecular weight HA
(HMW-HA) is a preferred biomaterial in the design of
many of these hydrogels due to its physiological role in
diarthrodial joint homeostasis and a key component of
articular cartilage and synovial fluid [10, 20–23]. An-
other key component in our currently used hydrogel
(Regenogel-OSP by Procore Ltd.) is fibrin, an autologous
component and a product of fibrinogen derived from
the patient’s own plasma. There have been previous
reports demonstrating the affinity of HA to fibrin as well
as their combination informing 3D scaffolds through co-
valent and ionic interactions [24–26] demonstrating im-
proved mechanical properties and resistance against
intra-articular deformation [27]. We hypothesized that
autologous platelet-rich plasma conjugated with HMW-
HA (HA-PRP) providing an authentic chemical conju-
gate made on site from the patient’s own fibrinogen and
PRP and a pre-activated form of HMW-HA sharing
enhanced stability, viscoelastic properties, and biocom-
patibility may result in a superior clinical and joint pres-
ervation outcome.
The objective this study was to compare the safety and
efficacy of intra-articular injections of HA with that of
HA-PRP, with saline as a control for symptomatic
treatment of OA using the cranial cruciate ligament
resection model in dogs. Functional methods of assess-
ment included clinical lameness score (including the
severity of pain), comfortable range of motion (CROM),
and gait analysis. Radiographic, gross pathologic, and
histologic assessments were also performed over the 20-
week study period.
Methods
Twelve adult beagle dog (2 years of age, body weight
mean = 8.8 kg, range = 6.7–10 kg) purpose-bred research
dogs were used. The dogs were permitted a 7-day accli-
mation period in the housing facilities prior to the initi-
ation of the study.
Preoperative assessments
Orthopedic examination by a trained veterinary ortho-
pedic surgeon was performed on each dog before inclu-
sion in the study (0 weeks). All limbs were evaluated to
ensure that no pre-existing orthopedic disorders were evi-
dent. CROM was measured using a standard goniometer,
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as previously described [15, 28–30]. Clinical lameness
scores were determined for each dog based on orthopedic
examination by the same trained orthopedic clinician
using modified criteria previously described [31] (Table 1).
The total sum of the clinical lameness score was recorded
for the statistical analysis.
Cranial cruciate ligament (CrCL) resection
On the day of surgery, the dogs were pre-medicated,
anesthetized, and prepared for aseptic surgical procedure
of the right stifle using a hanging limb technique. After
draping, each dog was positioned lateral recumbency,
and a curved parapatellar skin incision was made in the
right stifle joint. Another curved incision, similar to that
in the skin, was preformed through the fascia lata along
the cranial border of the biceps femoris. After separating
the fascia from the joint capsule, a stab incision was
made on the joint capsule and continued proximally and
distally along with the fascia late incision line. The
patella was retracted laterally, and the joint was opened.
With the exposure of the joint, it was inspected that
there was no evidence of pathological change in the
intra-articular structures. With the opened joint fully
flexed, the cranial cruciate ligament was identified and
resected with the #11 blade. The joint capsule and fascia
of the stifle joint were closed in one layer with 2-0 poly-
dioxanone (PDS-II®, Johnson & Johnson International,
USA). The subcutaneous tissue and skin were closed
using 2-0 polydiaonanone (PDS-II®, Johnson & Johnson
International, USA) and 2-0 polyamide (Nylon, AILEE,
Korea).
Postoperative medications were injected with the
tramadol (4 mg/kg, IV), meloxicam (0.2 mg/kg, IV), and
the cefazolin (25 mg/kg, IV) for 72 h after surgery. All
dogs were returned to their individual kennels and
allowed unrestricted activity in the housing facility. In
addition, all dogs were walked on a leash every day for
10–15min at a pace to ensure use of all four limbs.
A physical examination was performed daily for the first
3 days after surgery and any observations recorded, includ-
ing general condition, rectal temperature, appetite, and
activity. The operated limb was observed daily for signs of
swelling, erythema, heat, and dehiscence until suture
removal (10 days after surgery). The dogs were managed in
this way for 8weeks prior to the treatment in order to estab-
lish chronic osteoarthritis in the CrCL-resected limb.
Pre-treatment assessments
Eight weeks after CrCL resection (Pre), orthopedic
examination to assess stifle CROM, knee pain, and clin-
ical lameness score was performed on each dog. Kinetic
assessment of the operated limb was performed using a
pressure sensor walkway system (Tekscan, Inc., USA).




[2] Slightly abnormal stance (partial weight-bearing of the limb, but
the paw remains firmly in contact with floor)
[3] Markedly abnormal stance (partial weight-bearing of the limb, with
minimal contact between the paw and the floor)
[4] Severely abnormal stance (no weight-bearing)
Lameness at walk
[1] No lameness; normal weight-bearing on all strides observed
[2] Mild lameness with partial weight-bearing
[3] Obvious lameness with partial weight-bearing
[4] Marked lameness with no weight-bearing
Lameness at trot
[1] No lameness; normal weight-bearing on all strides observed
[2] Mild lameness with partial weight-bearing
[3] Obvious lameness with partial weight-bearing
[4] Marked lameness with no weight-bearing
Willingness to allow the clinician to lift the limb contralateral to the
affected limb
[1] Readily accepts contralateral limb elevation, bears full weight on
the affected limb for more than 30 s
[2] Offers mild resistance to contralateral limb elevation, bears full
weight on the affected limb for more than 30 s
[3] Offers moderate resistance to contralateral limb elevation and
replaces it in less than 30 s
[4] Offers strong resistance to elevation of contralateral limb and
replaces it in less than 10 s
[5] Refuses to raise contralateral limb
Range of motion (ROM)
[1] Full ROM
[2] Mild decrease (10–20%), with no crepitus
[3] Mild decrease (10–20%), with crepitus
[4] Moderate decrease (20–50%)
[5] Severe decrease (≥ 50%)
Pain at palpation/mobilization
[1] No pain elicited on palpation/mobilization of the affected joint
[2] Mild pain elicited, e.g., turns the head in recognition
[3] Moderate pain elicited, e.g., pulls the limb away
[4] Severe pain elicited, e.g., vocalizes or becomes aggressive
[5] Severe pain elicited, e.g., not allow examiner to palpate/mobilize
the joint





[5] Very severely poor
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Craniocaudal and mediolateral radiographic views of
the right stifle joint of each dog were obtained and
scored by one trained veterinary clinician blinded to the
treatment. The joints were examined for evidence of
periarticular osteophyte formation and enthesophyte for-
mation, subchondral bone sclerosis, articular margin ir-
regularity, and subchondral bone cyst formation. Scores
for the severity of osteoarthritic changes were assigned
as follows: none (0), minimal (1), mild (2), moderate (3),
or marked (4), as previously described for stifle joint
[32]. The sum of radiographic OA severity score was
recorded for statistical analysis.
Preparation of injection materials
The following are the proposed procedures for preparing
HA-PRP.
Preparation of PRP
Autologous PRP was prepared in each dog using double-
spin method formerly described [33]. Thirty milliliters of
fresh blood from each dog was collected in 10-mL tubes
containing 3.2% sodium citrate to prevent coagulation.
Before collecting the whole blood sample, 0.5 mL small
aliquot of the whole blood was retained for initial
complete cell count (CBC). Then, the blood sample was
centrifuged at 1,000g for 5 min at room temperature.
After the first centrifuge was completed, the upper
plasma and platelet fraction (PRP1) were transferred into
a sterile tube. The PRP1 fraction was centrifuged at 1,
500g for 15 min at room temperature. Two thirds of the
platelet-poor plasma (PPP) supernatant was drawn off,
and the platelet-containing pellet PRP2 was resuspended
in the remaining PPP. Through the above procedure, a
total of 4 mL of PRP was obtained for each dog and used
to make HA-PRP. Then, 0.5 mL aliquot of the obtained
PRP was removed and compared to the initial CBC
which should be at least four times the platelet counts of
the initial CBC.
Preparation of HA-PRP
Inactivated powder of HA (Regenogel-OSP, Procore-
biomed., Ltd., Israel) was used to make PRP-conjugated
HA (HA-PRP). All procedures for the preparation of
HA-PRP were followed by the manufacturer. A small
volume (1.2 mL) of sterile water from the 10mL water
for injection ample was drawn and added into the inacti-
vated powder of HA. The mixture of HA powder and
sterile water was mixed using a shaker at 2.8g for 10 min
at room temperature. Three milliliters of PRP obtained
by the former procedure was mixed with the activated
HA powder. Then, the HA-PRP solution was mixed at
room temperature for 30 min using a shaker at about
2.8g. Then, all the HA-PRP mixtures were injected in
each dog within 8 h.
Intra-articular treatments
Under sedation and analgesia, the right stifle joint of
each dog underwent aseptic arthrocentesis using a 23-
gage needle and 3-mL syringe to remove the synovial
fluid and ensure injections were intra-articular. The
volume of the aspirated fluid was recorded. Each right
stifle joint was then aseptically injected intra-articular
space through the same needle used for arthrocentesis
as follows:
 Control (saline) group: 2 mL of sterile 0.9% saline
was injected weekly for a total of four injections
beginning 8 weeks following CrCL resection.
 HA group: 2 mL of Hyaluronate® (Green Cross
Veterinary Products Co., Ltd, Korea) was injected
for a total of four injections beginning 8 weeks
following CrCL resection.
 HA conjugated with PRP (HA-PRP) group: 2 mL of
HA-PRP was injected once every 2 weeks (a total of
two injections) beginning 8 weeks following CrCL
resection.
All dogs recovered and returned to their individual
kennels and allowed unrestricted activity in the housing
facility. In addition, each dog was exercised on a leash
every day for 10-15 min at pace to confirm use of all
four limbs for the duration of the study.
Post-treatment assessments
Evaluation of the adverse effects
All dogs underwent daily physical examination and
palpation on the treated limb (evaluation of pain, heat,
and swelling) during the intra-articular injection period.
Blood works (CBC [Procyte DxTM, IDEXX Laboratories,
USA], chemistry [Catalyst DxTM, IDEXX Laboratories,
USA], and C-reactive protein [Catalyst DxTM, IDEXX
Laboratories, USA]) for all dogs were performed at 3
days after the first intra-articular injection.
Kinetics assessment
At weeks 2, 4, and 12 after completion of the first treat-
ment (10, 12, and 20 weeks after initiation of this study),
kinetic assessment was recorded using a pressure sensor
walkway (Tekscan, Inc., USA). All dogs were walked
across the walkway system in one direction with the
same examiner attempting to retain a consistent velocity
on a loose leash. At least five acceptable passes (3–5 gait
cycle), with video record, were acquired for each dog at
each time point. Passes were included for analysis when
the dogs walked at a regular pace with all four footprints
recorded for at least five gait cycles. The Tekscan soft-
ware (Tekscan, Inc., USA) was used to distinguish the
paw print for each footfall, which was then identified
manually as left front, left hind, right front, and right
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hind accordingly. In this way, at least five data points
were collected for calculating symmetry index (SI) and
weight distribution (WD) at each time point. The SI and
WD were calculated using the following formulas: SI (%)
= 100 − [(FI/Fc) × 100] (FI = parameter of the lame
extremity and Fc = parameter of the of the contralateral
extremity), WD (%) = the force-time integral (FTI, %
BW × s) of the affected limb/sum of the FTI.
Orthopedic examination
Orthopedic examination to evaluate knee CROM, clin-
ical lameness, and function assessments were performed
on each dog at weeks 2, 4, and 12 after the completion
of the first treatment. A single orthopedic clinician,
blinded to the treatment, performed these analyses at all
the time points.
Radiographic assessment
Under sedation with analgesia, radiographic assessments
of the stifle joints were performed on each dog at weeks
12 after completion of the first treatment. A single
trained clinician, blinded to treatment, analyzed all of
the radiographic images based on the criteria previously
described [32].
Post-mortem assessments
At 20 weeks, after the completion of the first treatment,
the dogs were humanely euthanatized. A full necropsy
was performed immediately after euthanasia by three
trained veterinary clinicians, who were blinded to the
treatment group and clinical findings. The affected stifle
joints from each dog were carefully dissected to evaluate
gross pathology of the articular cartilage and synovium.
Macroscopic alteration of the synovium (e.g., thickening
[fibrosis], discoloration, and vascularity) and articular
cartilage (e.g., cartilage structure, chondrocyte pathology,
and proteoglycan staining) was scored using the scoring
system set forth in the Osteoarthritis Research Society
International (OARSI) histopathology initiative [34].
Histologic assessments
After evaluating the macroscopic lesions of synovium
and articular cartilage, portions of the synovial tissue
were excised and fixed in formalin in the preparation for
histologic processing.
The proximal part of the operated tibia and the distal
part of the operated femur were excised and placed into
10% neutral buffered formalin. Bones were allowed to fix
for 5 days and then placed in 10% EDTA. After decalcifi-
cation was complete, the medial and lateral femoral
condyles and medial and lateral tibial plateaus were each
sliced into three sections approximately 2–4 mm thick
for processing, embedding in paraffin, microtome sec-
tioning (8 μm) and staining (Safranin O). Histologic
scoring of the osteochondral tissues was performed by
one veterinary clinician, blinded to the treatment, using
the OARSI histologic scoring system for canine OA.
Synovial tissue was routinely processed, sectioned (5
μm) and stained (hematoxylin and eosin [H&E]), and
scored using the criteria proposed by the OARSI [34].
Statistical analyses
The values were expressed as mean ± standard deviation
(SD). Statistical analysis was performed using Graphpad
Prism V 7.00 (Graphpad Software Inc., USA)
The CROM, clinical lameness score, and gait analysis
The repeated measures two-way analysis of variance
(ANOVA) with post-test Tukey’s multiple comparison
test was performed to assess the statistical significance
for CROM, clinical lameness score, and gait analysis (SI,
WD) within-group comparisons over time. Among the
group, comparisons were done using two-way ANOVA
with post-test Tukey’s multiple comparison test. Statis-
tical significance was accepted for a value of p < 0.05.
Macroscopic and microscopic lesion assessments
The Kruskal-Wallis one-way ANOVA test was per-
formed to assess the statistical significance of macro-
scopic and microscopic assessments. Furthermore,
Dunn’s multiple comparison test was performed to
evaluate the differences among the three groups. Statis-
tical significance was accepted for a value of p < 0.05.
Radiographic assessment
The repeated measures two-way ANOVA with post-test
Sidak’s multiple comparison test was performed to
evaluate the statistical significance for intra-group OA
score over time and inter-group OA score following the
specific time points.
Results
All 12 dogs successfully underwent CrCL resection, were
assigned injection treatment, and survived for the
intended period of the study.
CrCL resection model for OA
No evidence for lameness or OA was present in any dog
prior to CrCL resection. However, CrCL resection suc-
cessfully induced clinical signs of lameness and OA by the
time of intra-articular treatment (Table 2). Cranial draw
motion and tibia compression test showed the ruptured
cranial cruciate ligament and stifle joint instability. There
were no significant differences among the groups with
respect to the measures of kinetics, clinical lameness,
CROM, and radiographic assessments at the time of
treatment.
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Adverse events after intra-articular treatment
A dog (control [n = 1]) showed mild systemic inflamma-
tory reaction based on the result of C-reactive protein.
Two dogs (HA [n = 2]) showed non-weight-bearing
lameness following intra-articular treatment. All the
adverse events resolved within 3 days without the need
for additional treatment.
Clinical lameness score, CROM, and gait analysis
Post-CrCL resection (8 weeks), all dogs were lame with
an increase of difference in weight-bearing ability of
bilateral hind limbs (SI) and decrease of weight distribu-
tion (WD) and CROM (Figs. 1 and 2).
In the HA and HA-PRP groups, clinical lameness
scores decreased and CROM increased from 2 weeks
after the first intra-articular treatment (10 weeks),
whereas in the saline control group, the clinical lameness
score continued to increase after the injection and the
CROM remained unchanged. No significant differences
in lameness (p > 0.05) and CROM (p > 0.05) were
observed between the HA and HA-PRP groups over
time (Fig. 1).
Symmetry and weight distribution analyses revealed
improvements at weeks 12 and 20 in the two active
treatment groups (HA and HA-PRP) compared to the
saline control. Both active treatment groups showed a
consistent trend of reduction in symmetry index differ-
ences over time. At weeks 12 and 20, the improvement
was greater in the HA-PRP group than in the HA group,
although this was not statistically significant. There was
also no significant difference (p > 0.05) in weight distri-
bution between HA and HA-PRP at any time point
post-treatment (Fig. 2).
Radiographic OA
Radiographic OA severity score increased in the control
and active treatment groups over the 20-week evaluation
period. However, the differences in severity were not sta-
tistically significant within any group over time (p >
0.05) or among the groups (p > 0.05) at any time point
(Fig. 3).
Gross lesion assessments
Based on the gross lesion assessments of the treated
stifle joints at 20 weeks after the first treatment, all
groups had mild to severe articular cartilage damage
(predominantly in the medial compartment), with mild
to severe synovitis. Gross assessments of articular cartil-
age using the OARSI scoring system showed improve-
ment in the two active treatment groups compared to
control (Fig 4). Articular cartilage preservation, however,
was significantly better, as evidenced by a lower OARSI
mean score, only in the HA-PRP group when compared
to the control saline-injected group.
Histopathological assessments
HA and HA-PRP treatment resulted in the improvement
in osteochondral lesions, as manifested on histology by a
Table 2 Mean ± SD values for the outcome measures assessed before and after CrCL resection
Lameness score CROM (°) SI (PVF, %) SI (VI, %) WD (PVF, %) WD (VI, %) X-ray OA
Pre-CrCL resection 1 ± 0 126 ± 4.3 4.5 ± 3.9 9.6 ± 6 19.9 ± 2 18.6 ± 2.3 0 ± 0
8 weeks after CrCL resection 17.75 ± 2.5 103 ± 4.9 81 ± 27.4 78.9 ± 37.9 10.9 ± 3.2 10.5 ± 4.1 7 ± 1.2
Fig. 1 The clinical lameness score and CROM of all the experimental groups. Comparison of the values for lameness score (a) and CROM (b) in
the affected knees of dogs in the saline-, HA-, and HA-PRP-treated groups over the 20-week study period. *Statistically significant difference (p <
0.05) compared with the control group in specific time points, and the bar represents the mean with standard deviation. #Significant difference (p
< 0.05) within group comparison over time before (8 weeks) and after (10, 12, and 20 weeks) treatment. Arrow means the time point of the first
intra-articular treatment
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Fig. 2 Gait analysis on pressure sensor walkway. Comparison SI and WD in the affected knees of dogs in the saline-, HA-, and HA-PRP-treated
groups was over the 20-week study period. *Statistically significant difference (p < 0.05) compared with the control group in specific time points,
and the bar represents the mean with standard deviation. #Significant difference (p < 0.05) within group comparison over time before (8 weeks)
and after (10, 12, and 20 weeks) treatment. Arrow indicates the time point of the first intra-articular treatment
Fig. 3 Radiographic evaluation of all dogs before and after the intra-articular injection. The radiographs in the affected knees of dogs in the
control, HA, and HA-PRP groups (a) and comparison of the radiographic OA severity scores among three groups (b). No significant differences for
intra-group (p > 0.05) OA severity score over time and inter-group (p > 0.05) OA severity score following the specific time points were observed
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regular cartilage surface; more proteoglycan staining;
and fewer chondrocyte clusters. The extent of the im-
provement was larger in the HA-PRP group than in the
HA group. The active treatment groups had better
OARSI scores by all parameters for both the articular
cartilage and the synovium; however, those for articular
cartilage reached significance only for the HA-PRP
treated group (Fig. 5).
Discussion
No major complication (e.g., septic arthritis) was
observed following intra-articular injections in all groups
during the whole period of the study. However, two dogs
of the HA group showed non-weight-bearing lameness
after the first injection, which was relieved within 3 days
post-injection. The HA used in this study was made by
fermenting Streptococcus species. Naturally derived HA
compounds are known to result in minor local reactions
like stiffness and local inflammation flare at the injection
site [35]. This reaction is typically mild and self-limited,
resolving within 1–3 days. One dog of the control group
in this study showed systemic inflammatory reaction
according to the blood work after the first injection. This
may be associated with injection skill of the clinician
causing destruction of the joint structure [36].
Our study provides preliminary evidence that intra-ar-
ticular injections of HA and HA-PRP may result in sig-
nificant improvement in subjective severity of pain and
lameness scores (clinical lameness score) and CROM at
10 weeks (2 weeks after the first injection). Furthermore,
at 12 weeks (4 weeks after the first treatment), a signifi-
cant improvement was observed through an objective
measurement of weight-bearing (SI [PVF and VI], WD
[PVF and VI]) for dogs with clinical signs of OA involv-
ing a stifle joint. These data support the consideration of
an intra-articular injection of HA or HA-PRP as a feas-
ible treatment for OA in dogs.
HA used in this study has a high molecular weight (1.2
MDa). It is known that high molecular weight of HA
(HMW-HA) can be maintained for a long time in the
synovial space compared to the low molecular weight of
HA (LMW-HA) [37]. Marshall et al. reported that the
injection of HMW-HA at the knee joint 2 months after
the induction of accelerated canine osteoarthritis signifi-
cantly decreased the severity of the disease, based on the
gross and histological features [38]. Elmorsy et al.
Fig. 4 Macroscopic evaluation of the synovium and articular cartilage from all groups. Macroscopic lesions of the synovium (a) and articular
cartilage (c) in the affected knees of all experimental groups. Comparison of the OARSI scores of the gross lesion in the affected synovium and
articular cartilage (b, d). Proliferation and thickening with increased vascularity of the synovium were identified from the control and the HA
group (a, white arrows). Fibrillation and roughen articular surface were observed in the weight-bearing areas of the femoral condyle and the
tibial plateau (c, white arrowheads). *Significant difference (p < 0.05) between the treatment groups and the control group. OARSI scores of the
synovium (p > 0.05) and articular cartilage (p > 0.05) were not significantly different when comparing between HA and HA-PRP group
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reported less OA development, better friction coeffi-
cients, and improvement in histological scores, most
notably affecting the superficial cartilage layer, when
comparing HMW-HA to saline controls treated 5 weeks
after cranial cruciate ligament resection [39]. Kichuchi et
al. described that similar findings with HMW-HA being
more effective than LMW-HA in inhibiting cartilage
degradation when HA was injected immediately after
meniscectomy in rabbits [40]. Pashuck et al. reported
that injection of HMW-HA after 24 weeks after menisc-
ectomy in dogs was superior to LMW-HA in amelior-
ation of OA symptoms [30]. Our findings confirm the
beneficial clinical effects of HMW-HA by both subject-
ive and objective parameters at 10, 12, and 20 weeks
compared to the saline control group including gross
and histological grades of the synovium and a clear
trend showing less severe articular cartilage lesions
assessed grossly and histologically when compared with
the control group. The current data, consistent with the
results of previous studies, suggest that intra-articular in-
jection of HMW-HA may have beneficial effects amelior-
ating the symptoms associated with canine osteoarthritis.
The combination of HMW-HA and PRP, and in par-
ticular the more stable product of chemical conjugation
between the two components, was expected to enhance
both clinical and structural benefits of HMW-HA. Based
on this hypothesis, HA-PRP was injected at half the fre-
quency of that used for HMW-HA. Using that specific
protocol, there was however no statistically significant
advantage for HA-PRP over that of the HA group until
20 weeks of the study, based on CROM (p > 0.1) and
clinical lameness score (p > 0.7). There was, however, an
advantage albeit not significant for HA-PRP over HMW-
HA in gait analysis (SI of PVF [p > 0.2] and VI [p > 0.4],
Fig. 5 Microscopic assessments of the synovium and articular cartilage. Microscopic lesions of the synovium (a; H&E, scale bar = 100 μm) and
articular cartilage (c; Safranin O, scale bar = 100 μm [upper low], scale bar = 20 μm [lower low]) in the affected knees of all experimental groups.
Multiple cell layer (short arch) and villous hyperplasia (long arch) were observed in the synovium of the control and HA groups. Mild to moderate
inflammatory cell infiltrates including small lymphoid follicles were identified in the control group. The articular cartilage at the superficial zone
with an irregular surface (Arrowhead) was observed in the control group. The grade of proteoglycan staining (bidirectional arrows) was the
lowest in the control group, followed by the HA group. The large cell clusters in chondrocyte (arrows with short body) were observed frequently
compared with the HA and HA-PRP group. Comparison of the OARSI histopathologic scores in the affected synovium (b) and articular cartilage
(d). *Significant differences (p < 0.05) compared to the groups treated with saline. #Significant difference (p < 0.05) between the HA group and
the HA-PRP group
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WD of PVF [p > 0.4], and VI [p > 0.9]), in the joint
cartilage structure which was less susceptible to damage
as determined by gross and histological analysis in com-
parison with the HA-treated group. This may be associ-
ated with the specific properties of the HA-PRP conjugate
and in particular its residence time in the joint.
Several of HA derivatives have been used as hydrogel
with increased residence time. Milgilore et al. and
Benazzo et al. reported that HA hydrogel injection lasted
the effects of pain relief for up to 26 weeks in OA pa-
tients [41, 42]. Brown and Laurent reported that intra-
articular treatment of HA hydrogel could last up to 8
weeks in rabbit rheumatoid arthritis model [43]. PRP
may also play an important role in the maintenance of
hyaline-like chondrogenic phenotype, increase chondro-
cyte proliferation, and promotes proteoglycan synthesis,
and as a potent chemotactic factor for all cells of mesen-
chymal origin. It has been reported that intra-articular
injection of PRP reduce lameness score and preserve ar-
ticular cartilage in groups injected with PRP compared
to the control group [44]. The HA-PRP hydrogel used in
the current study may have sustained the chondropro-
tective effect of HA in the affected joint while maintain-
ing the articular cartilage regenerating effect of PRP.
The histological data showing a clear advantage in cartil-
age tissue preservation suggest that HA-PRP may also
alleviate the clinical signs of osteoarthritis for a longer
period of time in OA patients compared to conventional
HA by providing better, long-lasting protection from
damage induced OA.
In a previous study using a similar protocol in rabbit
femoral defect model, Liu et al. have shown that PRP was
effective in improving osteoarthritis histologically and bio-
chemically compared to the HA group [12]. Similarly,
using the same injection protocol, Guler et al. has
reported that PRP was more effective for alleviating clin-
ical symptoms caused by human OA in the early stages of
disease than HA [13]. In another study, OA patients who
received PRP or HA with the same protocol were followed
up at 3 and 6months after treatment. It was found that
pain scores were significantly lower in PRP-treated pa-
tients compared to HA-treated patients in all the time
points [14]. In the present study, the HA group was given
weekly injections for a total of four injections, and the
HA-PRP group was injected every 2 weeks for a total of
two injections. Although lower numbers of injections were
performed in the HA-PRP group, similar clinical out-
comes were observed when compared with the HA group.
Furthermore, a histologic evaluation revealed that the ar-
ticular cartilage was more preserved in the HA-PRP group
than in the HA group. These findings suggest that the
PRP component as well if the injections were carried out
at the same frequency as in the HA group may have
shown a more effective amelioration of OA symptoms.
According to radiographic assessments, none of the ma-
terials used in the current study were effective in amelior-
ating the development or progression of OA associated
with CrCL resection in dogs. These findings correspond
to Smith et al., who used intra-articular injection of HA in
a CrCL resection OA model in dogs [8]. Also, Pashuck et
al. described that intra-articular HA treatment was not ef-
fective to decrease the progression of OA in radiographic
evaluation after meniscal releasing in dogs [30]. Based on
the radiographic evaluation, no remarkable improvement
in ameliorating the development of OA was found in all
groups, but following the histological analysis, HA-PRP
seems to be effective in improving osteoarthritis at the
microscopic level.
Limitations of this study should be considered when
translating these data for clinical applicability. The injec-
tion protocol was performed based on the experimental
design, which is valid for pre-clinical study of OA thera-
peutics but does not exactly mimic the real clinical situ-
ation. There is no consensus or fully established protocols
for intra-articular injection of HA in veterinary medicine,
and different studies suggest different treatment regimens.
One such study proposed that three weekly injection
protocol is most suitable for decreasing lameness in dogs
[38], while Nganvongpanit et al. suggested one or two in-
jections in canine OA patients [45]. Establishing the cor-
rect protocol for improving OA may vary depending on
the type and nature of HA. Another limitation is the rela-
tively short follow-up of most of these studies including
our current study, making it difficult to determine long-
term differences, for example between HA and PRP.
Long-term, large-scale clinical trials are needed in order
to better establish the potential long-term beneficial ef-
fects of HA-PRP and HA used in this study.
Conclusions
This study to the best of our knowledge is the first
to compare the intra-articular injection of HA-PRP
hydrogel with conventional HMW-HA for the treat-
ment of canine OA. The results of our study suggest
that HA and HA-PRP, currently used for intra-ar-
ticular injections, are safe and effective in the ameli-
oration of clinical symptoms associated with OA in
dogs and HA-PRP can serve as a superior alternative
treatment for long-term joint preservation in OA
veterinary patients.
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